Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Equity (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Return on Equity for 7 consecutive years, with 0.17% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 51.0% year-over-year to 0.17%, compared with a TTM value of 0.17% through Dec 2025, up 51.0%, and an annual FY2025 reading of 0.2%, up 61.0% over the prior year.
  • Return on Equity was 0.17% for Q4 2025 at Keros Therapeutics, up from 0.09% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.17% in Q4 2025 and bottomed at 0.54% in Q4 2023.
  • Average Return on Equity over 5 years is 0.27%, with a median of 0.35% recorded in 2022.
  • The sharpest move saw Return on Equity crashed -114bps in 2021, then surged 51bps in 2025.
  • Year by year, Return on Equity stood at 0.25% in 2021, then plummeted by -59bps to 0.4% in 2022, then crashed by -34bps to 0.54% in 2023, then skyrocketed by 37bps to 0.34% in 2024, then soared by 151bps to 0.17% in 2025.
  • Business Quant data shows Return on Equity for KROS at 0.17% in Q4 2025, 0.09% in Q3 2025, and 0.03% in Q2 2025.